Discontinuation of Inpatient Review of Injectable Oncology Drugs
Effective June 16, 2021, Blue Cross and Blue Shield of North Carolina (Blue Cross NC) will no longer require prior plan approval in the inpatient setting for injectable oncology drugs billed under the medical benefit. There is no negative impact to members or providers as these drugs will no longer require prior approval in the inpatient setting. This change will help provide more efficient care for members receiving these treatments in the inpatient setting.
Actions for Providers
Following June 16, 2021, providers will no longer need to submit prior approval requests in the inpatient setting for injectable oncology drugs billed under the medical benefit. Please continue to visit our Medical Policy site if there are questions about which drugs require prior plan approval.
These changes apply to the following lines of business: Administrative Services Only (ASO), fully insured membership, Blue Card IPP Host and the State Health Plan (SHP).
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.